Intravenous and oral disopyramide after myocardial infarction.
Patients with acute myocardial infarction admitted to a coronary care unit were given either intravenous and oral disopyramide or matching placebo on admission and throughout their hospital stay. 199 patients entered the trial, and 138 were subsequently shown to have had a myocardial infarct. The placebo and study groups were well matched. There were no significant differences in mortality or observed arrhythmias between the two groups. These results do not confirm earlier observations that prophylaxis with disopyramide reduces mortality after acute myocardial infarction.
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000008:administration & dosage* / Q000097:blood; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D011725:Pyridines / Q000008:administration & dosage*
D011725:Pyridines; D004206:Disopyramide